DL
GILD icon

Daniel Loeb’s Gilead Sciences GILD Stock Holding History

Daniel Loeb’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-1,500,000
Closed -$113M – 54
2013
Q4 		$113M Buy
1,500,000
+1,000,000
+200% +$69.6M 1.94% 24
2013
Q3 		$31.4M Buy
+500,000
New +$29.9M 0.77% 28

Other funds holding GILD

BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Daniel Loeb's GILD Position: Q1 2014 in Review

Daniel Loeb sold out of Gilead Sciences (GILD) in Q1 2014, closing a stake of 1,500,000 shares — an estimated $113M sold.

Daniel Loeb first reported a position in GILD in Q3 2013 and held it in 2 quarters. The position peaked at $113M in Q4 2013. 1,189 funds tracked by Wall St. Rank hold GILD as of Q1 2014.

  • Daniel Loeb reported no remaining Gilead Sciences position as of Q1 2014 after selling out during the quarter.
  • Daniel Loeb sold 1,500,000 Gilead Sciences shares in Q1 2014, an estimated $113M.
  • Daniel Loeb first reported a position in Gilead Sciences in Q3 2013 and held it in 2 quarters.
  • Daniel Loeb's Gilead Sciences position peaked at $113M in Q4 2013.
  • 1,189 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2014.

Based on Third Point's 13F filing for Q1 2014, filed 15 May 2014.